NATR vs USNA

For growth investors, USANA Health Sciences, Inc.

(USNA) is the stronger pick with 8. 3% revenue growth year-over-year, versus 5. 7% for Nature's Sunshine Products, Inc. (NATR). Nature's Sunshine Products, Inc. (NATR) offers the better valuation at 24. 8x trailing P/E (23. 4x forward), making it the more compelling value choice. Analysts rate Nature's Sunshine Products, Inc. (NATR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Nature's Sunshine Products, Inc.

(NATR) is the cheapest at 24. 8x versus USANA Health Sciences, Inc. at 34. 5x. On forward P/E, USANA Health Sciences, Inc. is actually cheaper at 11. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nature's Sunshine Products, Inc.

(NATR) delivered a total return of +25. 6%, compared to -79. 7% for USANA Health Sciences, Inc. (USNA). Over 10 years, the gap is even starker: NATR returned +195. 6% versus USNA's -67. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nature's Sunshine Products, Inc.

(NATR) is the lower-risk stock at 0. 62β versus USANA Health Sciences, Inc. 's 1. 34β — meaning USNA is approximately 116% more volatile than NATR relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 12% for Nature's Sunshine Products, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), USANA Health Sciences, Inc.

(USNA) is pulling ahead at 8. 3% versus 5. 7% for Nature's Sunshine Products, Inc. (NATR). On earnings-per-share growth, the picture is similar: Nature's Sunshine Products, Inc. grew EPS 165. 0% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, NATR leads at 4. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nature's Sunshine Products, Inc.

(NATR) is the more profitable company, earning 4. 1% net margin versus 1. 2% for USANA Health Sciences, Inc. — meaning it keeps 4. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USNA leads at 5. 5% versus 5. 2% for NATR. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, USANA Health Sciences, Inc.

(USNA) trades at 11. 5x forward P/E versus 23. 4x for Nature's Sunshine Products, Inc. — 11. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USNA: 74. 9% to $35. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nature's Sunshine Products, Inc.

(NATR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 62), +195. 6% 10Y return). Both have compounded well over 10 years (NATR: +195. 6%, USNA: -67. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.